Thorbald van Hall

40PUBLICATIONS
123CO-AUTHORS
Molecular targetsApplied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Cancer therapy (excl. chemotherapy and radiation therapy)Tumour immunologyPredictive and prognostic markers
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (40)

|Nov 13, 2025
Pyroglutamation of cell surface proteins CD47 and TRP1 by glutaminyl cyclase modulates therapeutic antibody binding.

Anneloes van der Plas-van Duijn, Levi M T Winkelman, Claire Lensen

|May 28, 2025
TEIPP-vaccination in checkpoint-resistant non-small cell lung cancer: a first-in-human phase I/II dose-escalation study.

Mitchell Emmers, Marij J P Welters, Michelle V Dietz

|Jan 12, 2025
Cancer vaccines compensate for the insufficient induction of protective tumor-specific immunity of CD3 bispecific antibody therapy.

Jim Middelburg, Gaby Schaap, Marjolein Sluijter

|Jan 09, 2024
Neutralizing Antibodies Impair the Oncolytic Efficacy of Reovirus but Permit Effective Combination with T cell-Based Immunotherapies.

Christianne Groeneveldt, Priscilla Kinderman, Lisa Griffioen

|Jan 03, 2024
T-cell stimulating vaccines empower CD3 bispecific antibody therapy in solid tumors.

Jim Middelburg, Marjolein Sluijter, Gaby Schaap

|Oct 29, 2023
Longitudinal evaluation of the biodistribution and cellular internalization of the bispecific CD3xTRP1 antibody in syngeneic mouse tumor models.

Gerwin Gerhard Wemke Sandker, Jim Middelburg, Evienne Wilbrink

Pageof 7

Frequent Collaborators

14 joint publications

Sjoerd H van der Burg

6 joint publications

Christianne Groeneveldt

5 joint publications

Diana J M van den Wollenberg

5 joint publications

Nadine van Montfoort